A PAT Solution for Automated Mill Control - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A PAT Solution for Automated Mill Control
The authors describe the implementation of an on-line particle-size analyzer on an active pharmaceutical ingredient milling operation at a commercial site.


Pharmaceutical Technology
Volume 34, Issue 1

Conclusions

The PAT initiative encourages the pharmaceutical industry to embrace new analytical approaches with the aim of transforming process development and manufacture. Realtime process monitoring and automated control are essential elements of this transformation, which has the potential to improve product quality, cut production costs and reduce time to market.

This case study highlights the availability, relevance, and benefits of a commercially available PAT solution for particle-size analysis. For pharmaceutical products, particle size is often a critical quality attribute that directly impacts performance and/or manufacturability, so better control delivers significant gains. An on-line system was used to transform a stand-alone manual mill into an automated process unit that will integrate into a manufacturing facility with a distributed control system or statistical process control. The Insitec analyzer used is a proven process solution for real-time particle sizing that additionally meets pharmaceutical industry requirements for clean in place, sterilize in place, validation and 21 CFR Part 11, the federal regulations providing guidelines on electronic records and electronic signatures in the United States.

The benefits of automating control include improved product quality, increased throughput, and less waste. Furthermore, automation opens up a route to semicontinuous operation and real-time release, important long-term goals in reaching operational excellence.

Qualification of an automated mill with closed-loop control delivers a solution that could potentially be used elsewhere in the company for both pilot- and full-scale operations. Semicontinuous operation with extended run times is a realistic and attractive alternative to conventional batch operations.

Alon Vaisman* is an application development manager at Malvern Instruments, Enigma Business Park, Grovewood Road, Malvern, Worcestershire, WR14 1XZ, UK, tel: +44 (0)1684 892456, fax +44 (0)1684 892789
. Yanhui Hu is a principal quality-by-design engineer in the quality assurance division at Abbott Laboratories.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here